Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
about
Emerging Threats in Antifungal-Resistant Fungal PathogensClinical perspectives on echinocandin resistance among Candida speciesEchinocandin resistance: an emerging clinical problem?Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care centerPractice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.Resistance patterns and clinical significance of Candida colonization and infection in combat-related injured patients from iraq and afghanistan.New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study.Pharmacodynamics of amphotericin B deoxycholate, amphotericin B lipid complex, and liposomal amphotericin B against Aspergillus fumigatus.Susceptibility to echinocandins of Candida spp. strains isolated in Italy assessed by European Committee for Antimicrobial Susceptibility Testing and Clinical Laboratory Standards Institute broth microdilution methods.Multiple cyp51A-based mechanisms identified in azole-resistant isolates of Aspergillus fumigatus from China.High-Level Pan-Azole-Resistant AspergillosisPosttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Stepwise emergence of azole, echinocandin and amphotericin B multidrug resistance in vivo in Candida albicans orchestrated by multiple genetic alterations.Characterisation of Candida within the Mycobiome/Microbiome of the Lower Respiratory Tract of ICU PatientsEchinocandin Resistance in Candida.In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales OrderQuantitative Analysis of Single-Nucleotide Polymorphism for Rapid Detection of TR34/L98H- and TR46/Y121F/T289A-Positive Aspergillus fumigatus Isolates Obtained from Patients in Iran from 2010 to 2014.A Prospective Surveillance Study of Candidaemia: Epidemiology, Risk Factors, Antifungal Treatment and Outcome in Hospitalized Patients.Fluconazole and Echinocandin Resistance of Candida glabrata Correlates Better with Antifungal Drug Exposure Rather than with MSH2 Mutator Genotype in a French Cohort of Patients Harboring Low Rates of Resistance.Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in Candida spp. and Aspergillus spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion MethodResistance of Candida spp. to antifungal drugs in the ICU: where are we now?Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.Mechanisms of echinocandin antifungal drug resistance.New facets of antifungal therapy.Diagnostic of Fungal Infections Related to Biofilms.In Vivo Efficacy of Liposomal Amphotericin B against Wild-Type and Azole-Resistant Aspergillus fumigatus Isolates in Two Different Immunosuppression Models of Invasive Aspergillosis.Detection of Polish clinical Aspergillus fumigatus isolates resistant to triazoles.Epidemiological investigation of Candida species causing bloodstream infection in paediatric small bowel transplant recipients.Candida species isolated from different body sites and their antifungal susceptibility pattern: Cross-analysis of Candida albicans and Candida glabrata biofilms.[Strategies for antifungal treatment failure in intensive care units].Determination of antifungal susceptibility patterns among the environmental isolates of Aspergillus fumigatus in Iran.Next-generation sequencing offers new insights into the resistance of Candida spp. to echinocandins and azoles.Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.Molecular Tools for the Detection and Deduction of Azole Antifungal Drug Resistance Phenotypes in Aspergillus Species.Biomarker-based strategy for early discontinuation of empirical antifungal treatment in critically ill patients: a randomized controlled trial.Isavuconazole susceptibility of clinical Aspergillus fumigatus isolates and feasibility of isavuconazole dose escalation to treat isolates with elevated MICs.Aspergillus fumigatus cyp51A polymorphisms, an insight on their significance.Voriconazole-Susceptible and Voriconazole-Resistant Aspergillus fumigatus Coinfection.Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms.Responding to the emergence of antifungal drug resistance: perspectives from the bench and the bedside
P2860
Q26750816-0B0DE08E-5FE0-4832-94B9-8138F88CFA9CQ28082538-DF20C882-C58C-4CAB-B0E3-8DA8CC98580EQ28544739-333450C4-C6D3-4ECA-A405-76AB62E38F9FQ34058322-4003217F-8878-46B7-9B35-0C05B6FA0185Q34532546-366A651D-CA63-4FCF-88F7-9085744C474CQ35072030-61A57487-B977-427E-BDBC-EC5422BF42F6Q35177179-D558AEFB-5D59-4C19-9A12-C4DE6AE6CA6BQ35385786-04414587-51A0-4541-8B83-67AE76392C16Q35635472-3CF6E55E-A58C-45D2-A437-ED4B905A166AQ35746043-222F4BEE-747E-484E-B496-9077799BA2D8Q35757617-8EB21CB9-765E-4447-924A-157334E6B570Q35880078-5DF9A42C-0682-4E00-8B94-39F3827D1B86Q36008037-E85101C2-410D-44AB-9BEB-B27A283A662CQ36024184-D8F7A2B4-94C7-47A4-A9A9-A4CE7BD85CB9Q36276186-6556D340-294F-4911-AF8B-D0C37E19B5E2Q36290764-443730BD-A35B-45F1-8F9E-CE6494F8EEBBQ36439193-B2AA5ADE-71E3-4F40-8ED1-A221A4C749D1Q37012419-F6BDF68F-9364-49DC-B788-E3E6A89AB6E2Q37528498-D699EE66-40A0-4DB9-B70A-4E4642028F7EQ37538775-968029E1-3C06-4323-B758-AA5F269B5961Q38236893-16D316DE-4D85-4663-927F-516D1F9C6F0DQ38254290-7F14E876-5104-4C66-B3A1-7240CBBE91C8Q38550402-B18B43FA-5676-4F17-8520-95AA7708D681Q38797864-B785D25A-8F67-47E5-8178-189B988CB653Q38853348-3F1F6AB3-8DE4-49E5-9F67-02211DEA6FF2Q40248126-F8CD0BAF-30C3-416C-A4EB-973FA7FFC814Q40279616-DCF0D3A0-2743-4D5B-A5C9-3B101995E2B1Q40352038-7ADF9D46-EF0A-4E3D-8F17-DFFCBA10048EQ40424798-E13E5B39-B0E0-4F8E-B161-7BDD94B63791Q41010354-E67AE30F-DD49-4625-BCFB-DBDD39A0E640Q41108420-87FFE025-6367-4AAD-889A-82011B8AAB22Q41199783-BC674A4A-3DB2-46A0-8D61-53CD75A514AEQ45199703-0A440DDC-D6C2-45C8-9720-FECEA46FD0B9Q46307503-1A33BEC0-FEC0-4192-943A-066E68552332Q47678193-588AD508-A811-46FE-BDC5-F26006D9A13FQ50094753-44581462-1F50-4DA5-B262-65BA548A1874Q52597957-7C3D81CF-6134-4DC3-B57A-06A0C6AB1D9EQ53789869-3AED22D7-9C52-48A7-BBEA-1E3FE87AA163Q55511181-CCE3FBAF-2440-4AE3-BCDC-700B7D20AAE2Q58772251-CA670997-489C-47A0-A6A0-8B92CF885CC8
P2860
Breakpoints for antifungal agents: an update from EUCAST focussing on echinocandins against Candida spp. and triazoles against Aspergillus spp.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Breakpoints for antifungal age ...... zoles against Aspergillus spp.
@en
type
label
Breakpoints for antifungal age ...... zoles against Aspergillus spp.
@en
prefLabel
Breakpoints for antifungal age ...... zoles against Aspergillus spp.
@en
P50
P1476
Breakpoints for antifungal age ...... azoles against Aspergillus spp
@en
P2093
Manuel Cuenca-Estrella
P356
10.1016/J.DRUP.2014.01.001
P577
2013-12-01T00:00:00Z